60 DEGREES PHARMA INC (SXTP) Stock Price, Quote, News and Summary
NASDAQ:SXTP - Nasdaq - US83006G2030 - Common Stock
SXTP Quote and Key Statistics
60 DEGREES PHARMA INC
NASDAQ:SXTP (1/17/2025, 8:00:01 PM)
After market: 0.7853 -0.04 (-5.16%)0.828
+0 (+0.31%)
SXTP Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -113% | ||
| ROE | -138.85% | ||
| Debt/Equity | 0.02 |
SXTP Performance and Technical Analysis
SXTP Ownership and Analysts
SXTP Latest News and Analysis
These stocks are moving in today's pre-market session
Get insights into the top gainers and losers of Wednesday's pre-market session.
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment....
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs....
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
60 Degrees Pharmaceuticals expands tafenoquine trial for babesiosis to Brigham and Women’s, targeting severe cases with unmet medical needs. ...
About SXTP
Company Profile
60 Degrees Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Company Info
60 DEGREES PHARMA INC
1025 Connecticut Avenue Nw, Suite 1000
WASHINGTON WASHINGTON DC US
Employees: 3
Company Website: https://60degreespharma.com/
Investor Relations: https://investors.60degreespharma.com/
Phone: 12023275422
SXTP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 71.36 | 688.94B | ||
| JNJ | JOHNSON & JOHNSON | 14.36 | 353.99B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.77 | 349.49B | ||
| MRK | MERCK & CO. INC. | 16.46 | 247.70B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.48 | 206.53B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 194.99B | ||
| PFE | PFIZER INC | 10.19 | 149.04B | ||
| SNY | SANOFI-ADR | 12.29 | 127.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.11 | 114.17B | ||
| ZTS | ZOETIS INC | 28.8 | 74.84B | ||
| GSK | GSK PLC-SPON ADR | 8.21 | 68.21B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B |